ArticleNature2023
The NK cell receptor NKp46 recognizes ecto-calreticulin on ER-stressed cells.
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 108 papers.
0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed
30.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 162 citations in OpenAlex.
- Advances in natural killer cell immunotherapy for hematologic malignancies.Cancer biology & therapy · 2026Review
- The Unfolded Protein Response as a Modulator of Cancer-Immune Cell Communication in the Tumour Microenvironment.Journal of cellular and molecular medicine · 2026Review
- DAMPs, PAMPs, and Alarmins: From Mechanism to Therapy.MedComm · 2026Review
- Inhibition of KDEL Receptors Remodels the Tumor Microenvironment for T Cell Independent Tumor Regression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Peptide Loading Complex in Cancer: From Peptide Translocation, Editing, and Loading into MHC-I to a Potential Therapeutic Target.Current medical science · 2026Review
- SBRT embedded in low-dose RT plus αPD-1 (immuno-EclipseRT, iERT) elicits CD8Nature communications · 2026Article
- EGFRxCD16 bispecific antibodies orchestrate superior NK cell-mediated lysis of ovarian cancer and NSCLC cell lines in combination with oncolytic viruses.Cancer immunology, immunotherapy : CII · 2026Article
- Endoplasmic reticulum stress and the unfolded protein response in lung diseases: molecular pathways and therapeutic interventions.The Journal of pathology · 2026Review
- Acquisition of Vimentin by trogocytosis inhibits the NK cell-mediated immune response against circulating tumour cells (CTCs).Cellular & molecular immunology · 2026Article
- Harnessing Cuproptosis for Antitumor Immunity: A Review of Current Evidence and Therapeutic Strategies.Molecular carcinogenesis · 2026Review
- Immunological consequences of senescence in physiology and pathology.Journal of translational medicine · 2026Review
- Cord blood natural killer cell-derived extracellular vesicles inhibit Zika virus infectivity through ITGB2/perforin-mediated envelope disruption in vitro and in vivo.Bioactive materials · 2026Article
- Ultrasound-activated piezoelectric Bi@Bi-MOF enables STING-mediated immunotherapy for implant-associated infections.Journal of nanobiotechnology · 2026Article
- RadD fromeLife · 2026Article
- Endoplasmic reticulum stress in antitumor immunity and immunotherapy resistance: mechanisms and therapeutic implications.Molecular cancer · 2026Review
- Novel NK cell-like phenotype expressing CCR5 and its ligands elicits tumor-specific acquired immunity to carcinomatous peritonitis via host NK-derived IFN-γ.Journal for immunotherapy of cancer · 2026Article
- Immunogenic cell death as a cornerstone for combination therapies with immune checkpoint blockade.Molecular cancer · 2026Review
- CAR-NK cell therapy for hematologic malignancies: advances, challenges and optimization strategies.Molecular cancer · 2026Review
- Induction of caspase-mediated suppression of interferon signaling potentiates viral oncolysis of resistant tumor cells.Cell communication and signaling : CCS · 2026Article
- Ultrasound-activated MoS₂@Fe₃O₄ nanoplatform orchestrates biofilm disruption and immune reprogramming in implant-associated infections.Journal of nanobiotechnology · 2026Article
48 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
16 authors at 3 institutions in 4 countries.
Sumit Sen Santara *Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.
Dian-Jang Lee *Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7268-3240
Ângela CrespoProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-6731-8190
Jun Jacob HuProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7098-6272
Caitlin WalkerProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.
Xiyu MaProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.
Ying ZhangProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-1116-2182
Sourav ChowdhuryDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA.
Karla F Meza-SosaProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0095-2357
Mercedes LewandrowskiProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.
Haiwei ZhangProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.
Marjorie RoweProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-3562-5567
Arthur McClellandCenter for Nanoscale Systems, Faculty of Arts and Sciences, Harvard University, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-4798-5954
Hao WuProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7281-8579
Caroline JunqueiraProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA. caroline.junqueira@childrens.harvard.edu.ORCID http://orcid.org/0000-0003-0545-0986
Judy LiebermanProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA. judy.lieberman@childrens.harvard.edu.ORCID http://orcid.org/0000-0002-6200-4715
Boston Children's Hospital · USHarvard University · USIndian Institute of Science Education and Research Kolkata · IN
Funding
MOLECULAR BASIS OF VIRAL INFECTIVITYT32AI007245 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Aaron Gregory Schmidt · 1985 to 2026
$11.3MDecidual NK response to infectionR01AI145862 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI LIEBERMAN, JUDY · 2019 to 2023
$4.2MEndogenous ligand of the NK activating receptor NKp46R21AI150671 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI LIEBERMAN, JUDY · 2020 to 2021
$487kNIAID NIH HHS R01 AI145862NIAID NIH HHS R21 AI150671NIAID NIH HHS T32 AI007245
Abstract
Natural killer (NK) cell kill infected, transformed and stressed cells when an activating NK cell receptor is triggered
Indexed as
CalreticulinEndoplasmic Reticulum StressKiller Cells, NaturalNatural Cytotoxicity Triggering Receptor 1AlarminsAnimalsAntigens, LyCell MembraneEndoplasmic ReticulumHumansImmunity, InnateImmunological SynapsesLung NeoplasmsMelanoma, ExperimentalMiceZika VirusAlarminsAntigens, LyCalreticulinCALR protein, humanNatural Cytotoxicity Triggering Receptor 1NCR1 protein, humanNcr1 protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.